To the Editor,
We read with great interest the recent meta-analysis by Dr. Wu et al. [1], which investigated the efficacy of corticosteroids in patients with severe community-acquired pneumonia (CAP). A total of severe randomized controlled trials involving 1689 patients were included, and the primary finding is that in patients with severe CAP, adjunctive corticosteroids can provide survival benefits and improve clinical outcomes without increasing adverse events. We have some different opinions.
First, in the sensitivity analysis, this review used leave-one-out analyses (removing one trial at a time from each meta-analysis), and they reported that all the results remained stable. However, this result may be biased by inadequate study inclusion. We performed another literature search on the basis of the previous systematic reviews and identified another two trials (the Santeon-CAP Trial [2] and Snijders et al.’s Trial [3]) that should be included. After the inclusion of these two trials, the sensitivity analysis became unstable in the leave-one-out analysis, and the result became non-significant after excluding Dequin et al.’s trial [4] (Fig. 1, overall effect: RR 0.77, 95% 0.57–1.03). Besides, two recent adequately powered, rigorously designed randomized trials [4, 5] of severe CAP have reported opposite outcomes, suggesting that the efficacy of corticosteroids in severe CAP may be heterogeneous. In addition, the instability of the results of the current meta-analysis suggests that further studies may be needed.
Fig. 1.
sensitivity analysis of the effect of corticosteroids on mortality in community-acquired pneumonia. Note: in the leave-one-out sensitivity analysis, the effect on all-cause mortality became non-significant after excluding Dequin et al.’s trial
Second, within all included trials, there is some concern [6] about Sabry’s [7] trial. All included trials reported in-hospital or 30-day mortality as the outcome. However, in Sabry’s trial, the authors used extreme short-term mortality (8-day) as the primary outcome, which was less than the reported median time to death in CAP (nine days, which means almost half of all deaths were not observed) [8]. Thus, to reach a stable result, it is reasonable to perform another sensitivity analysis by excluding this trial. In Fig. 1, both pooled analysis with or without Sabry’s [7] trial was performed and the result remained non-significant.
Acknowledgements
Not applicable.
Author contributions
S.C. raised the question, and C.H. was responsible for analysis and writing. All authors have reviewed and approved the manuscript.
Funding
None.
Availability of data and materials
Not applicable.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
None.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Wu JY, Tsai YW, Hsu WH, Liu TH, Huang PY, Chuang MH, Liu MY, Lai CC. Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2023;27(1):274. doi: 10.1186/s13054-023-04561-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Wittermans E, Vestjens SMT, Spoorenberg SMC, Blok WL, Grutters JC, Janssen R, Rijkers GT, Smeenk F, Voorn GP, van de Garde EMW, et al. Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial. Eur Respir J. 2021;58(2). [DOI] [PubMed]
- 3.Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181(9):975–982. doi: 10.1164/rccm.200905-0808OC. [DOI] [PubMed] [Google Scholar]
- 4.Dequin PF, Meziani F, Quenot JP, Kamel T, Ricard JD, Badie J, Reignier J, Heming N, Plantefeve G, Souweine B, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;388:1931–1941. doi: 10.1056/NEJMoa2215145. [DOI] [PubMed] [Google Scholar]
- 5.Meduri GU, Shih MC, Bridges L, Martin TJ, El-Solh A, Seam N, Davis-Karim A, Umberger R, Anzueto A, Sriram P, et al. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med. 2022;48(8):1009–1023. doi: 10.1007/s00134-022-06684-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Wan YD, Sun TW, Liu ZQ, Zhang SG, Wang LX, Kan QC. Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest. 2016;149(1):209–219. doi: 10.1378/chest.15-1733. [DOI] [PubMed] [Google Scholar]
- 7.Sabry NA. Omar EE-D: corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacol Pharm. 2011;2(1):73–81. doi: 10.4236/pp.2011.22009. [DOI] [Google Scholar]
- 8.Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, Winzeler B, Bingisser R, Elsaesser H, Drozdov D, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385(9977):1511–1518. doi: 10.1016/S0140-6736(14)62447-8. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Not applicable.